| Dermatitis, Atopic
Opzelura vs Nemluvio
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Opzelura vs Nemluvio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNemluvio has a higher rate of injection site reactions vs Opzelura based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nemluvio but not Opzelura, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Opzelura
Nemluvio
At A Glance
Topical
Twice daily
JAK inhibitor
SC injection
Every 4 weeks
IL-31 receptor antagonist
Indications
- Dermatitis, Atopic
- Vitiligo
- Prurigo nodularis
- Dermatitis, Atopic
Dosing
Dermatitis, Atopic Apply a thin layer topically twice daily to affected areas of up to 20% body surface area; do not use with occlusive dressings; adults and pediatric patients 12 years and older: max one 60 gram tube per week or one 100 gram tube per 2 weeks; pediatric patients 2 to 11 years: max one 60 gram tube per 2 weeks.
Vitiligo Apply a thin layer topically twice daily to affected areas of up to 10% body surface area; max one 60 gram tube per week or one 100 gram tube per 2 weeks.
Prurigo nodularis (<90 kg) Initial dose of 60 mg (two 30 mg injections) SC, followed by 30 mg SC every 4 weeks.
Prurigo nodularis (>=90 kg) Initial dose of 60 mg (two 30 mg injections) SC, followed by 60 mg SC every 4 weeks.
Dermatitis, Atopic Initial dose of 60 mg (two 30 mg injections) SC, followed by 30 mg SC every 4 weeks; after 16 weeks, patients who achieve clear or almost clear skin may receive 30 mg every 8 weeks.
Contraindications
—
- Known hypersensitivity to nemolizumab-ilto or any excipient in NEMLUVIO
Adverse Reactions
Most common (>=1%) - Atopic Dermatitis nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis, rhinorrhea, upper respiratory tract infection, COVID-19, application site reactions, pyrexia, white blood cell decreased
Most common (>=1%) - Nonsegmental Vitiligo application site acne, application site pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema, pyrexia
Most common (>=1%) Headache, dermatitis atopic, eczema, eczema nummular (prurigo nodularis trials); headache, arthralgia, urticaria, myalgia (atopic dermatitis trials).
Serious Type 1 hypersensitivity reactions (IgE-mediated), including facial angioedema.
Pharmacology
Ruxolitinib is a JAK inhibitor that inhibits JAK1 and JAK2, which mediate signaling of cytokines and growth factors important for hematopoiesis and immune function; JAK signaling involves STAT recruitment to cytokine receptors, activation, and nuclear localization leading to modulation of gene expression.
Nemolizumab-ilto is a humanized IgG2 monoclonal antibody that inhibits IL-31 signaling by binding selectively to IL-31 receptor alpha (IL-31 RA); IL-31 is a cytokine involved in pruritus, inflammation, epidermal dysregulation, and fibrosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Opzelura
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
Nemluvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Opzelura
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Nemluvio
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (4/8)
Humana
Opzelura
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Nemluvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OpzeluraView full Opzelura profile
NemluvioView full Nemluvio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.